BioSpace News Archive

Drug Development

Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US

Clarity Pharmaceuticals is pleased to announce that the US-based diagnostic 64Cu SAR-Bombesin trial for patients with PSMA-negative prostate cancer is open for recruitment.

September 5, 2022
·
8 min read
Drug Development

Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO

Dizal reported the promising safety and pharmacokinetic data from the global Phase I study of DZD1516 in patients with HER2 positive metastatic breast cancer who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncology Annual Meeting.

September 5, 2022
·
4 min read
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal announced positive topline results from the first pivotal study of sunvozertinib in platinum-pretreated NSCLC Patients with EGFR exon20ins mutations at the European Society for Medical Oncology Annual Meeting.

September 5, 2022
·
5 min read
Drug Development

Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.

September 5, 2022
·
6 min read
Bertis Announces Proteomic Based Research Results of New Biomarker for Ovarian Cancer Diagnosis

Bertis announced on the 5th that the research results of their search for protein biomarkers for early diagnosis of high-grade serous ovarian cancer were published in the September issue of the international scientific journal, Journal of Proteome Research.1 This press release features multimedia.

September 5, 2022
·
5 min read
Deals

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Clarus Therapeutics Holdings, Inc. announced that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

September 5, 2022
·
6 min read